Proteção contra leptospirose induzida por LipL32 coadministrada ou fusionada à LTB

Detalhes bibliográficos
Autor(a) principal: Grassmann, André Alex
Data de Publicação: 2011
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Repositório Institucional da UFPel - Guaiaca
Texto Completo: http://guaiaca.ufpel.edu.br/handle/123456789/1285
Resumo: Leptospirosis is an infectious disease that affects humans, wild and domestic animals worldwide. Pathogenic spirochetes from the Leptospira genus are the causative agents of this zoonosis. The several Leptospira species have noted antigenic diversity, even within the same species. This is the main reason current bacterin vaccines have limitations, such as adverse effects and short term immunity, restricting their use in human populations. The need for effective leptospirosis vaccines promoted studies on characterization of new vaccine candidates. The 32 kDa outer membrane lipoprotein, LipL32, is the most abundant protein in the whole leptospira proteome, it is conserved in all pathogenic serovars and absent in saprophytes. This protein is immunogenic and able to bind to mammalian extracellular matrix. However, LipL32 subunit vaccines did not protect animals against challenge. In an attempt to solve this, we use LipL32 fused and coadministered with B subunit of the Escherichia coli heat-labile enterotoxin (LTB) to enhance the immune response. LTB is a non-toxic molecule with immunoestimulatory and immunomodulatory properties. The recombinant proteins rLTB, rLipL32 and rLTB::LipL32 were expressed in E. coli, purified and characterized. Female hamsters were distributed in groups as follows: rLTB; rLTB+rLipL32; rLTB::LipL32, homologous bacterin; PBS. The serum from each animal was collected for humoral immune response determination by ELISA. The animals were challenged with 5×LD50 dose of Leptospira interrogans strain Fiocruz L1-130. Both treatments induced high titers of anti-rLipL32 antibodies. The rLTB+rLipL32 and rLTB::LipL32 treatments afforded significant protective response upon challenge, when compared to control groups (p<0.05). No prior study with leptospirosis had used LTB as the adjuvant, or fused antigens in an attempt to control this disease. Furthermore, this is the first report of a protective subunit vaccine using rLipL32 as the antigen, and an important contribution towards the development of improved leptospirosis vaccines.
id UFPL_19640b878aef5345a1242d5208d2e0b9
oai_identifier_str oai:guaiaca.ufpel.edu.br:123456789/1285
network_acronym_str UFPL
network_name_str Repositório Institucional da UFPel - Guaiaca
repository_id_str
spelling 2014-08-20T13:32:57Z2011-05-162014-08-20T13:32:57Z2011-02-28GRASSMANN, André Alex. Protection against leptospirosis induced by LipL32 co-administered or fused to LTB. 2011. 51 f. Dissertação (Mestrado em Biotecnologia) - Universidade Federal de Pelotas, Pelotas, 2011.http://guaiaca.ufpel.edu.br/handle/123456789/1285Leptospirosis is an infectious disease that affects humans, wild and domestic animals worldwide. Pathogenic spirochetes from the Leptospira genus are the causative agents of this zoonosis. The several Leptospira species have noted antigenic diversity, even within the same species. This is the main reason current bacterin vaccines have limitations, such as adverse effects and short term immunity, restricting their use in human populations. The need for effective leptospirosis vaccines promoted studies on characterization of new vaccine candidates. The 32 kDa outer membrane lipoprotein, LipL32, is the most abundant protein in the whole leptospira proteome, it is conserved in all pathogenic serovars and absent in saprophytes. This protein is immunogenic and able to bind to mammalian extracellular matrix. However, LipL32 subunit vaccines did not protect animals against challenge. In an attempt to solve this, we use LipL32 fused and coadministered with B subunit of the Escherichia coli heat-labile enterotoxin (LTB) to enhance the immune response. LTB is a non-toxic molecule with immunoestimulatory and immunomodulatory properties. The recombinant proteins rLTB, rLipL32 and rLTB::LipL32 were expressed in E. coli, purified and characterized. Female hamsters were distributed in groups as follows: rLTB; rLTB+rLipL32; rLTB::LipL32, homologous bacterin; PBS. The serum from each animal was collected for humoral immune response determination by ELISA. The animals were challenged with 5×LD50 dose of Leptospira interrogans strain Fiocruz L1-130. Both treatments induced high titers of anti-rLipL32 antibodies. The rLTB+rLipL32 and rLTB::LipL32 treatments afforded significant protective response upon challenge, when compared to control groups (p<0.05). No prior study with leptospirosis had used LTB as the adjuvant, or fused antigens in an attempt to control this disease. Furthermore, this is the first report of a protective subunit vaccine using rLipL32 as the antigen, and an important contribution towards the development of improved leptospirosis vaccines.A leptospirose é uma doença infecciosa que afeta humanos e animais silvestres e domésticos em todo mundo. As espiroquetas patogênicas do gênero Leptospira são os agentes causadores desta zoonose. As diversas espécies de leptospiras possuem notada diversidade antigênica, inclusive em uma mesma espécie. Esta característica resulta em limitação das atuais vacinas bacterinas que não induzem proteção cruzada entre os diferentes sorovares. Além disso, estas vacinas geram efeitos adversos e imunidade de curta duração, restringindo seu uso em populações humanas. A necessidade de novas vacinas eficazes contra a leptospirose estimulou estudos para caracterizar novos antígenos vacinais. A lipoproteína de membrana externa de 32 kDa, LipL32 é a proteína mais abundante no proteoma total da leptospira, conservada entre todos os sorovares patogênicos e ausente nas leptospiras saprófitas. Esta proteína é imunogênica e possui habilidade de ligar-se à matriz extracelular de mamíferos. Porém, animais inoculados com vacinas de subunidade utilizando LipL32 não sobrevivem ao desafio. Em função disso, utilizamos LipL32 fusionada e co-administrada com a subunidade B da enterotoxina termolábil de Escherichia coli (LTB) para melhorar a resposta imune. LTB é uma molécula atóxica com reconhecida atividade imunoestimuladora e imunomoduladora. As proteínas recombinantes rLTB, rLipL32 e rLTB::LipL32 foram produzidas em E. coli, purificadas e caracterizadas. Hamsters fêmeas foram distribuídas em grupos e inoculadas com duas doses, da seguinte forma: rLTB; rLTB+rLipL32; rLTB::LipL32, bacterina homóloga e PBS. Soro foi coletado individualmente para determinação da resposta imune humoral por ELISA. Os animais foram desafiados com uma dose de 5×DL50 de Leptospira interrogans cepa Fiocruz L1-130. Os tratamentos induziram altos títulos de anticorpos anti-rLipL32. Os tratamentos rLTB+rLipL32 e rLTB::LipL32 induziram resposta protetora significativa frente ao desafio quando comparados com os grupos controle (p<0,05). Nenhum estudo anterior usou LTB como adjuvante para uma vacina contra leptospirose, tampouco antígenos fusionados com o intuito de controlar esta doença. Além disso, este é o primeiro relato de indução de imunidade protetora utilizando rLipL32 como vacina de subunidade, uma importante contribuição para o desenvolvimento de vacinas mais eficazes contra leptospirose.application/pdfporUniversidade Federal de PelotasPrograma de Pós-Graduação em BiotecnologiaUFPelBRBiotecnologiaLeptospirosisRecombinant vaccineLeptospiraLeptospiroseVacina recombinanteLTBLipL32CNPQ::CIENCIAS BIOLOGICAS::BIOQUIMICA::BIOLOGIA MOLECULARProteção contra leptospirose induzida por LipL32 coadministrada ou fusionada à LTBProtection against leptospirosis induced by LipL32 co-administered or fused to LTBinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesishttp://lattes.cnpq.br/3880433527026304http://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4723107D9Dellagostin, Odir AntônioGrassmann, André Alexinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFPel - Guaiacainstname:Universidade Federal de Pelotas (UFPEL)instacron:UFPELORIGINALdissertacao_andre_grassmann.pdfapplication/pdf1497268http://guaiaca.ufpel.edu.br/xmlui/bitstream/123456789/1285/1/dissertacao_andre_grassmann.pdf73f55a329ef2c9be70227b63b45785a2MD51open accessTEXTdissertacao_andre_grassmann.pdf.txtdissertacao_andre_grassmann.pdf.txtExtracted Texttext/plain90702http://guaiaca.ufpel.edu.br/xmlui/bitstream/123456789/1285/2/dissertacao_andre_grassmann.pdf.txtdac7b6bf0e361d0b538c9f30eae8f670MD52open accessTHUMBNAILdissertacao_andre_grassmann.pdf.jpgdissertacao_andre_grassmann.pdf.jpgGenerated Thumbnailimage/jpeg1860http://guaiaca.ufpel.edu.br/xmlui/bitstream/123456789/1285/3/dissertacao_andre_grassmann.pdf.jpg663448a1415c5c7e9666debd075c72e3MD53open access123456789/12852019-08-23 09:27:43.367open accessoai:guaiaca.ufpel.edu.br:123456789/1285Repositório InstitucionalPUBhttp://repositorio.ufpel.edu.br/oai/requestrippel@ufpel.edu.br || repositorio@ufpel.edu.br || aline.batista@ufpel.edu.bropendoar:2019-08-23T12:27:43Repositório Institucional da UFPel - Guaiaca - Universidade Federal de Pelotas (UFPEL)false
dc.title.por.fl_str_mv Proteção contra leptospirose induzida por LipL32 coadministrada ou fusionada à LTB
dc.title.alternative.eng.fl_str_mv Protection against leptospirosis induced by LipL32 co-administered or fused to LTB
title Proteção contra leptospirose induzida por LipL32 coadministrada ou fusionada à LTB
spellingShingle Proteção contra leptospirose induzida por LipL32 coadministrada ou fusionada à LTB
Grassmann, André Alex
Leptospirosis
Recombinant vaccine
Leptospira
Leptospirose
Vacina recombinante
LTB
LipL32
CNPQ::CIENCIAS BIOLOGICAS::BIOQUIMICA::BIOLOGIA MOLECULAR
title_short Proteção contra leptospirose induzida por LipL32 coadministrada ou fusionada à LTB
title_full Proteção contra leptospirose induzida por LipL32 coadministrada ou fusionada à LTB
title_fullStr Proteção contra leptospirose induzida por LipL32 coadministrada ou fusionada à LTB
title_full_unstemmed Proteção contra leptospirose induzida por LipL32 coadministrada ou fusionada à LTB
title_sort Proteção contra leptospirose induzida por LipL32 coadministrada ou fusionada à LTB
author Grassmann, André Alex
author_facet Grassmann, André Alex
author_role author
dc.contributor.authorLattes.por.fl_str_mv http://lattes.cnpq.br/3880433527026304
dc.contributor.advisorLattes.por.fl_str_mv http://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4723107D9
dc.contributor.advisor1.fl_str_mv Dellagostin, Odir Antônio
dc.contributor.author.fl_str_mv Grassmann, André Alex
contributor_str_mv Dellagostin, Odir Antônio
dc.subject.eng.fl_str_mv Leptospirosis
Recombinant vaccine
topic Leptospirosis
Recombinant vaccine
Leptospira
Leptospirose
Vacina recombinante
LTB
LipL32
CNPQ::CIENCIAS BIOLOGICAS::BIOQUIMICA::BIOLOGIA MOLECULAR
dc.subject.por.fl_str_mv Leptospira
Leptospirose
Vacina recombinante
LTB
LipL32
dc.subject.cnpq.fl_str_mv CNPQ::CIENCIAS BIOLOGICAS::BIOQUIMICA::BIOLOGIA MOLECULAR
description Leptospirosis is an infectious disease that affects humans, wild and domestic animals worldwide. Pathogenic spirochetes from the Leptospira genus are the causative agents of this zoonosis. The several Leptospira species have noted antigenic diversity, even within the same species. This is the main reason current bacterin vaccines have limitations, such as adverse effects and short term immunity, restricting their use in human populations. The need for effective leptospirosis vaccines promoted studies on characterization of new vaccine candidates. The 32 kDa outer membrane lipoprotein, LipL32, is the most abundant protein in the whole leptospira proteome, it is conserved in all pathogenic serovars and absent in saprophytes. This protein is immunogenic and able to bind to mammalian extracellular matrix. However, LipL32 subunit vaccines did not protect animals against challenge. In an attempt to solve this, we use LipL32 fused and coadministered with B subunit of the Escherichia coli heat-labile enterotoxin (LTB) to enhance the immune response. LTB is a non-toxic molecule with immunoestimulatory and immunomodulatory properties. The recombinant proteins rLTB, rLipL32 and rLTB::LipL32 were expressed in E. coli, purified and characterized. Female hamsters were distributed in groups as follows: rLTB; rLTB+rLipL32; rLTB::LipL32, homologous bacterin; PBS. The serum from each animal was collected for humoral immune response determination by ELISA. The animals were challenged with 5×LD50 dose of Leptospira interrogans strain Fiocruz L1-130. Both treatments induced high titers of anti-rLipL32 antibodies. The rLTB+rLipL32 and rLTB::LipL32 treatments afforded significant protective response upon challenge, when compared to control groups (p<0.05). No prior study with leptospirosis had used LTB as the adjuvant, or fused antigens in an attempt to control this disease. Furthermore, this is the first report of a protective subunit vaccine using rLipL32 as the antigen, and an important contribution towards the development of improved leptospirosis vaccines.
publishDate 2011
dc.date.available.fl_str_mv 2011-05-16
2014-08-20T13:32:57Z
dc.date.issued.fl_str_mv 2011-02-28
dc.date.accessioned.fl_str_mv 2014-08-20T13:32:57Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv GRASSMANN, André Alex. Protection against leptospirosis induced by LipL32 co-administered or fused to LTB. 2011. 51 f. Dissertação (Mestrado em Biotecnologia) - Universidade Federal de Pelotas, Pelotas, 2011.
dc.identifier.uri.fl_str_mv http://guaiaca.ufpel.edu.br/handle/123456789/1285
identifier_str_mv GRASSMANN, André Alex. Protection against leptospirosis induced by LipL32 co-administered or fused to LTB. 2011. 51 f. Dissertação (Mestrado em Biotecnologia) - Universidade Federal de Pelotas, Pelotas, 2011.
url http://guaiaca.ufpel.edu.br/handle/123456789/1285
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Pelotas
dc.publisher.program.fl_str_mv Programa de Pós-Graduação em Biotecnologia
dc.publisher.initials.fl_str_mv UFPel
dc.publisher.country.fl_str_mv BR
dc.publisher.department.fl_str_mv Biotecnologia
publisher.none.fl_str_mv Universidade Federal de Pelotas
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFPel - Guaiaca
instname:Universidade Federal de Pelotas (UFPEL)
instacron:UFPEL
instname_str Universidade Federal de Pelotas (UFPEL)
instacron_str UFPEL
institution UFPEL
reponame_str Repositório Institucional da UFPel - Guaiaca
collection Repositório Institucional da UFPel - Guaiaca
bitstream.url.fl_str_mv http://guaiaca.ufpel.edu.br/xmlui/bitstream/123456789/1285/1/dissertacao_andre_grassmann.pdf
http://guaiaca.ufpel.edu.br/xmlui/bitstream/123456789/1285/2/dissertacao_andre_grassmann.pdf.txt
http://guaiaca.ufpel.edu.br/xmlui/bitstream/123456789/1285/3/dissertacao_andre_grassmann.pdf.jpg
bitstream.checksum.fl_str_mv 73f55a329ef2c9be70227b63b45785a2
dac7b6bf0e361d0b538c9f30eae8f670
663448a1415c5c7e9666debd075c72e3
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFPel - Guaiaca - Universidade Federal de Pelotas (UFPEL)
repository.mail.fl_str_mv rippel@ufpel.edu.br || repositorio@ufpel.edu.br || aline.batista@ufpel.edu.br
_version_ 1813710181047992320